OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, headquartered in New York City, with additional offices in various global locations. The firm manages approximately $5 billion in assets and specializes in private equity and venture capital investments across the healthcare sector, including pharmaceuticals, biotechnology, medical devices, and healthcare services. OrbiMed invests in companies at various stages, from early startups to established multinationals, and typically seeks to take majority stakes in its private equity investments. The firm employs fundamental analysis to guide its investment decisions and offers a range of financial services, including debt financing and structured capital, to both public and private healthcare companies. OrbiMed's investment strategy encompasses a broad spectrum of healthcare-related opportunities, targeting investments globally, primarily in North America, Europe, and Asia.
Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
iECURE is a biotechnology company focused on developing gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. The company employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted therapeutic interventions without being limited by specific genetic mutations. Its initial programs concentrate on addressing metabolic "loss of function" disorders, which often have significant unmet medical needs. Through its innovative approach, iECURE aims to provide effective treatments for devastating diseases that currently lack viable options.
Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
Iroko Pharmaceuticals, LLC is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing and commercializing innovative pharmaceutical products for pain management. Founded in 2007, the company markets a range of prescription pain medications, including Indocid, Aldomet, TIVORBEX, ZORVOLEX, and VIVLODEX, which are designed to address various pain management needs, particularly for patients with osteoarthritis and acute pain. Iroko utilizes proprietary technology to formulate lower-dose nonsteroidal anti-inflammatory drugs (NSAIDs), improving therapeutic options for patients. The company has established a robust distribution and sales network, extending its reach to more than 40 countries, and aims to enhance healthcare by revitalizing existing medications through new applications and geographic markets.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.